Non-Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Axis Targeting Agents – French Trends

1. Abstract
1.1. Background: This study describes the real-world frequency, management and resource use of adverse events (AEs) of special interest in non-metastatic castration-resistant prostate cancer (nmCRPC) patients receiving androgen receptor axis targeting agents (ARATs), in France.